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Outcome Studies—Are All
Antihypertensive Drugs Created Equal?
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Several recent prospective, randomized trials leave us with
the perception that there are little if any differences in
outcome among various drug classes in patients with essen-
tial hypertension. The Captopril Prevention Project
(CAPPP), which compared an angiotensin-converting en-
zyme (ACE) inhibitor with conventional therapy (i.e.,
agents, diuretic beta-blockers) in more than 10,000 patients,
reported similar rates of heart attack, stroke and cardiovas-
cular and all-cause mortality in patients who were treated
with either an ACE inhibitor (captopril) or conventional
therapy (diuretic agents and beta adrenergic blocking
agents) (1). A comparison of the Systolic Hypertension in
the Elderly Program (SHEP) (2) with the recently pub-
lished Systolic Hypertension in Europe study (Syst-Eur) (3)
in patients with isolated systolic hypertension again shows a
remarkably similar reduction in cardiovascular morbidity
and mortality and all-cause mortality with treatment strat-
egy based on a diuretic agent (chlorthalidone) and one based
on a calcium antagonist (nitrendipine). This was true in the
nondiabetic population, whereas in the diabetic population
the calcium antagonist seemed to have an advantage over
diuretic therapy (4). Nitrendipine-based therapy had a
greater reduction in all-cause and cardiovascular mortality in
the diabetic than in the nondiabetic patient with isolated
systolic hypertension (4). But even in the diabetic hyperten-
sive population, differences, if any, are far from clear cut. In
the Appropriate Blood Pressure Control in Diabetes
(ABCD) study (5) there were fewer cardiovascular events in
the ACE inhibitor arm than in the calcium antagonist arm,
but there was no difference in the renal outcome between
the two strategies. After four years of follow up, renal
function (as measured by creatinine clearance), micropro-
teinuria and diabetic neuropathy were exactly the same in
the two treatment groups. Similarly, in the UK diabetes
study (6), it did not seem to matter whether blood pressure
was lowered by a beta-blocker (atenolol) or an ACE
inhibitor (captopril) in the diabetic hypertensive patient—
outcome was similar.
Does this mean that as long as blood pressure is lowered
sufficiently, the means by which it is achieved is unimpor-
tant? Clearly, high blood pressure is a powerful risk factor,
and its reduction is prone to exert benefits that can override
small synergistic or antagonistic properties of antihyperten-
sive drugs. However, before we conclude that the drug does
not matter as long as the blood pressure is low, we should
remember that recent studies also have documented some
extracardiovascular effects of antihypertensive drugs that are
prone to influence our selection of antihypertensive drugs in
the future. The data of Lever et al. (7), suggesting a 30%
decrease in malignancy with ACE inhibitors as compared
with other antihypertensive drugs, are provocative and
require urgent confirmation. Hypertension and malignancy
share several risk factors, such as smoking, diabetes, obesity
and alcohol consumption. Malignancies, therefore, are com-
mon in the hypertensive population (8), and any treatment
strategy that could diminish this risk would be extremely
important. In contrast, the recent data suggesting that the
long-term use of diuretic agents is associated with a low
grade risk of renal cell carcinoma (9,10) are perturbing, and
they too need to be confirmed. Finally, the drastic reduction
of dementia of the Alzheimer type in the Syst-Eur study
(11) by a calcium antagonist–based treatment strategy is yet
another hint that calcium antagonists are an “appropriate
alternative” in the elderly, as suggested by the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC-VI) (12). Demen-
tia and cognitive impairment are more common in the
hypertensive than in the normotensive patient, and any
treatment strategy that could prevent these would be wel-
come. Thus, although all antihypertensive drugs lower
blood pressure (by definition), and so far, differences in
cardiovascular outcome, if any, between various antihyper-
tensive strategies seem to be small, it could well be that the
true merit of various therapeutic strategies will quite unex-
pectedly stand and fall with the effect of these drugs on
extracardiovascular disorders.
Correspondence: Dr. Messerli, Ochsner Clinic, 1514 Jefferson
Highway, New Orleans, Louisiana 70121. E-mail: Fmesserli@
aol.com.
REFERENCES
1. Hansson L, Lindholm LH, Niskanen L, et al., for the Captopril
Prevention Project (CAPPP) Study Group. Effects of angiotensin-
converting-enzyme inhibition compared with conventional therapy on
From the Department of Internal Medicine, Section on Hypertensive Diseases,
Ochsner Clinic, New Orleans, Louisiana.
Journal of the American College of Cardiology Vol. 34, No. 5, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00356-3
cardiovascular morbidity and mortality in hypertension: the Captopril
Prevention Project (CAPPP). Lancet 1999;353:611–6.
2. SHEP Cooperative Research Group. Prevention of stroke by antihy-
pertensive drug treatment in older persons with isolated systolic
hypertension: final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA 1991;265:3255–64.
3. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in
Europe (Syst-Eur) Trial Investigators. Randomised double-blind
comparison of placebo and active treatment for older patients with
isolated systolic hypertension. Lancet 1997;350:757–64.
4. Tuomilehto J, Rastenyte D, Birkenhager WH, et al., for the Systolic
Hypertension in Europe Trial Investigators. Effects of calcium-
channel blockade in older patients with diabetes and systolic hyper-
tension. N Engl J Med 1999;340:677–84.
5. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier
RW. The effect of nisoldipine as compared with enalapril on cardio-
vascular outcomes in patients with non–insulin-dependent diabetes
and hypertension. N Engl J Med 1998;338:645–52.
6. U.K. Prospective Study Group. Tight blood pressure control and risk
of macrovascular and microvascular complications in type 2 diabetes:
UKPDS 38. BMJ 1998;317:703–13.
7. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I–
converting enzyme protect against risk of cancer? Lancet 1998;352:
179–84.
8. Hamet P. Cancer and hypertension: an unresolved issue (review).
Hypertension 1996;28:321–4.
9. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase
the risk of renal cell carcinoma? Am J Cardiol 1999;83:1090–3.
10. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352:
1691– 6.
11. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in
randomised double-blind placebo-controlled Systolic Hypertension
in Europe (Syst-Eur) trial. Lancet 1998;352:1347–51.
12. The Sixth Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure. Arch
Intern Med 1997;157:2413–46.
1653JACC Vol. 34, No. 5, 1999 Messerli
November 1, 1999:1652–3 Outcome Studies—Are All Antihypertensive Drugs Equal?
